- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in gilead
Gilead To Acquire German Biotech Firm MYR For About 1.15 Billion Euros
The German company expects to submit an application for the accelerated approval of Hepcludex, which works by blocking viral entry into liver cells, in the United States in the second half of 2021.
Read More
Gilead Cuts 2020 Sales Outlook As COVID-19 Drug Remdesivir Falls Short
Sales of the company's flagship HIV drugs rose 8% from a year earlier to $4.55 billion, as patient demand normalized following disruption related to the pandemic.
Read More
Sales Of First Big COVID-19 Drug, Remdesivir, May Disappoint
Remdesivir has become the standard of care for patients hospitalized with severe COVID-19. But many doctors remain wary of using it more widely, raising questions about lofty analyst sales forecasts for a drug that could eventually be eclipsed by newer treatments.
Read More
Gilead To Pay $97 Million To Settle U.S. Kickback Probe
Gilead's actions enabled the Foster City, California-based drugmaker to boost revenue, ran from June 2007 to December 2010, and violated the federal False Claims Act, the department said.
Read More
Gilead To Buy Cancer Drugmaker Immunomedics For $21 Billion
Gilead's offer will be funded with $15 billion in cash on hand, and through $6 billion in newly issued debt, according to the drugmaker.
Read More
Gilead To Buy Cancer Drugmaker Immunomedics For $21 Billion
The offer will be funded with $15 billion in cash on hand, and through $6 billion in newly issued debt, according to the drugmaker.
Read More
Gilead Raises Sales Outlook To Include COVID-19 Treatment Remdesivir
Gilead's second-quarter sales fell nearly 10% from a year earlier to $5.1 billion, short of the average analyst estimate of $5.3 billion, according to Refinitiv.
Read More
Gilead Targets Remdesivir Supply For Two Million COVID-19 Patients By Year-End
Gilead's expectations of two million treatment courses suggests sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course
Read More
Six Indian companies applied to CDSCO for permission to manufacture, market Remdesivir drug: Health Ministry
Six Indian companies applied to CDSCO for permission to manufacture, market Remdesivir drug: Health Ministry
Read More
AstraZeneca Contacted Gilead Over Potential Megamerger
Gilead, AstraZeneca and other drugmakers, including Eli Lilly and Co, Pfizer and Merck & Co, are racing to develop vaccines or treatments for COVID-19
Read More
Gilead Trades That Made Millions On COVID-19 Drug News Raise Eyebrows
Gilead's shares jumped nearly 10% following a media report detailing encouraging partial data from trials of the U.S. company's experimental drug remdesivir in severe COVID-19 patients.
Read More
Gilead In Talks With Indian Drugmakers To Produce Remdesivir For Treatment Of COVID-19
The company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to licence remdesivir for developing countries.
Read MoreGilead Deepens Galapagos Ties With $5.1 Billion Deal
The investment in Galapagos, which comes nearly four years after the firms partnered to develop a drug targeting inflammatory diseases, includes an upfront payment of $3.95 billion and a $1.1 billion equity investment from Gilead.
Read More
